Business
Meta Connect developer conference
(Andrej Sokolow/Getty Images)
AI Wars

Cage match on hold: For once, Musk and Zuckerberg are on the same side of a fight

Thanks to AI, Zuck and Musk are unlikely allies

Jack Raines

In June 2023, Elon Musk tweeted that he was “up for a cage match” with Mark Zuckerberg, and Zuck accepted the challenge, posting “send me location” in an Instagram story.

A year and a half later, while the two billionaires still haven’t fought in the octagon, they have formed an unlikely alliance against a common competitor: OpenAI. Over the weekend, The Wall Street Journal reported that Meta is urging California’s attorney general to block OpenAI’s conversion to a for-profit entity, following in Tesla CEO Musk’s footsteps. Musk, an OpenAI founder, previously sued OpenAI for bailing on its nonprofit mission, though OpenAI posted a lengthy statement last week saying Musk wanted OpenAI to be for-profit from the start.

The Journal reported that Meta said in a letter to AG Rob Bonta that allowing OpenAI to become a for-profit company would set a dangerous precedent by letting the “non-profit” investors benefit from tax write-offs until the company was ready to go public:

“If OpenAI’s new business model is valid, non-profit investors would get the same for-profit upside as those who invest the conventional way in for-profit companies while also benefiting from tax write-offs bestowed by the government.”

Of course beyond the skewed incentive structure that might be encouraged by allowing a nonprofit to convert to a for-profit, Meta has another reason for wanting this deal blocked: OpenAI is one of its biggest AI competitors. Meta has led the charge with open-sourcing AI through its Llama models. Meanwhile, Musk’s xAI has raised $12 billion to buy GPUs and compete with OpenAI as well.

OpenAI raised $6.6 billion in October, valuing the company at $157 billion, but this fundraise was contingent on the company converting to a for-profit entity. California blocking this move would be a huge blow to the ChatGPT creator and benefit Zuckerberg and Musk’s AI ambitions.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.